| scholarly article | Q13442814 |
| P50 | author | Xinyu Wang | Q59191607 |
| P2093 | author name string | Lizhen Wang | |
| Min Yang | |||
| Yuping Xu | |||
| Junjie Yan | |||
| Donghui Pan | |||
| Runlin Yang | |||
| Qianhuan Huang | |||
| Zhicheng Bai | |||
| Yunyun Pan | |||
| P2860 | cites work | Inconsistency of HER2 test raises questions | Q80595700 |
| Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus | Q83256315 | ||
| Structural basis for high-affinity HER2 receptor binding by an engineered protein | Q27664013 | ||
| 64Cu-labeled affibody molecules for imaging of HER2 expressing tumors | Q34140651 | ||
| Engineering of affibody molecules for therapy and diagnostics. | Q34317761 | ||
| PET of EGFR expression with an 18F-labeled affibody molecule | Q34429075 | ||
| Comparison of two site-specifically (18)F-labeled affibodies for PET imaging of EGFR positive tumors | Q34446069 | ||
| Evaluation of (89)Zr-pertuzumab in Breast cancer xenografts | Q34473478 | ||
| F-Labeled GRPR Agonists and Antagonists: A Comparative Study in Prostate Cancer Imaging | Q34912606 | ||
| 68Ga-DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET | Q36085489 | ||
| Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors | Q36372344 | ||
| Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease | Q36615272 | ||
| [18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography | Q36627997 | ||
| Engineering antibodies for clinical applications | Q36826527 | ||
| Radiofluorination using aluminum-fluoride (Al18F) | Q36880744 | ||
| First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination | Q36931413 | ||
| ErbB-directed immunotherapy: antibodies in current practice and promising new agents | Q37059364 | ||
| Evaluation of 99mTc-peptide-ZHER2:342 Affibody® molecule for in vivo molecular imaging | Q37504847 | ||
| Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. | Q37730252 | ||
| Targeting HER2 in ovarian and uterine cancers: challenges and future directions | Q38249126 | ||
| Targeting HER2 for the treatment of breast cancer | Q38317974 | ||
| Preliminary evaluation of [18F]AlF-NOTA-MAL-Cys39-exendin-4 in insulinoma with PET. | Q38901439 | ||
| Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with (188)Re. | Q38950538 | ||
| PET imaging of prostate tumors with 18F-Al-NOTA-MATBBN. | Q39004440 | ||
| A new (68)Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging | Q39015002 | ||
| Pilot study of a novel (18)F-labeled FSHR probe for tumor imaging | Q39037392 | ||
| Three methods for 18F labeling of the HER2-binding affibody molecule Z(HER2:2891) including preclinical assessment | Q39081855 | ||
| Influence of nuclides and chelators on imaging using affibody molecules: comparative evaluation of recombinant affibody molecules site-specifically labeled with ⁶⁸Ga and ¹¹¹In via maleimido derivatives of DOTA and NODAGA. | Q39147880 | ||
| PET of HER2-positive pulmonary metastases with 18F-ZHER2:342 affibody in a murine model of breast cancer: comparison with 18F-FDG. | Q39348841 | ||
| Potential of PET to predict the response to trastuzumab treatment in an ErbB2-positive human xenograft tumor model | Q39381175 | ||
| Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled affibody protein | Q39713379 | ||
| On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. | Q39882876 | ||
| Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules. | Q50866938 | ||
| 89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients. | Q53057899 | ||
| First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule. | Q53073318 | ||
| Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold. | Q54667220 | ||
| P433 | issue | 7 | |
| P304 | page(s) | 1170-1178 | |
| P577 | publication date | 2017-04-09 | |
| P1433 | published in | Journal of Cancer | Q6294901 |
| P1476 | title | PET of HER2 Expression with a Novel 18FAl Labeled Affibody | |
| P478 | volume | 8 |
| Q92503500 | A Comprehensive Review of Non-Covalent Radiofluorination Approaches Using Aluminum [18F]fluoride: Will [18F]AlF Replace 68Ga for Metal Chelate Labeling? |
| Q90307333 | Affibody Molecules as Targeting Vectors for PET Imaging |
| Q90581932 | ImmunoPET: Concept, Design, and Applications |
| Q47653328 | Microglial activation mediates chronic mild stress-induced depressive- and anxiety-like behavior in adult rats. |
| Q90589324 | PET imaging of a 68Ga labeled modified HER2 affibody in breast cancers: from xenografts to patients |
| Q90012672 | Visualization of gene therapy with a liver cancer-targeted adeno-associated virus 3 vector |
Search more.